In wake of unexpected patient deaths, MacroGenics closes down PhII cancer trial – Endpoints News
Business News In wake of unexpected patient deaths, MacroGenics closes down PhII cancer trial Endpoints News MacroGenics closes solid tumor clinical trial after 7 people die FierceBiotech Enoblituzumab Trial Ended Early Due to Safety Concerns in Head and Neck Squamous Cell Carcinoma OncLive Source: Business News
